A multicultural group practicing yoga together in a bright studio

TMates vs Yucca Health: GLP-1 Comparison 2026

TMates vs Yucca Health: pricing, medication type, clinical support, and which budget-conscious GLP-1 patient each program fits. Both programs’ prices verified July 2026 or later; each price carries its own date in the table below.

By RangeYourselfUpdated September 3, 20264 min read

Quick answer

Yucca Health typically wins on sticker price for compounded GLP-1. Both prescribe compounded medication, so compare them on the specific product, plan term, and terms you'd actually be buying rather than on program positioning.

Side-by-side comparison

Feature	TMates	Yucca Health
Best for	Compounded GLP-1 with hands-on clinical touch	Low advertised entry price on compounded GLP-1 with plain FDA disclosures and all-50-state provider coverage
Medication type	Compounded GLP-1 with bundled clinical support	Compounded semaglutide and tirzepatide, once-weekly injection ('Semaglutide+' / 'Tirzepatide+'); also sells NAD+ and Sermorelin (out of registry scope)
Pricing model	Monthly subscription, dose-tier pricing	6-month prescription plans billed monthly/quarterly/6-month; advertised new-patient entry pricing; full pricing shared after intake
Semaglutide price	From $158/mo (compounded semaglutide, 12-month plan; $249/mo month-to-month); medication and visits included	Compounded. Verbatim from tryyucca.com 2026-09-03: 'Semaglutide plans start at $125 per month with the 6-month plan ($750 total); the month-to-month plan is $146 per month.' The 6-month rate dropped $146 -> $125; $146 is now the published month-to-month rate. Page still notes 'Pricing is shared after intake once eligibility is confirmed.'
Tirzepatide price	From $167/mo (compounded tirzepatide, 12-month plan; $297/mo month-to-month)	Compounded. Verbatim from tryyucca.com 2026-09-03: 'Tirzepatide plans start at $225 per month with the 6-month plan ($1,350 total); the month-to-month plan is $258 per month.' The 6-month rate dropped $258 -> $225; $258 is now the published month-to-month rate.
Key watchout	The $158 headline is the compounded SEMAGLUTIDE plan (12-month term; $249/mo month-to-month). Tirzepatide costs more ($167/mo on a 12-month plan, $297 month-to-month), confirm your product and term at checkout	The $125/mo figure is the 6-month-commitment semaglutide rate ($750 total); month-to-month is $146/mo. Dose-level pricing is still shared only after intake ('Pricing is shared after intake once eligibility is confirmed'), so confirm your dose's rate. Confirm your dose's ongoing rate at intake. Pharmacies are not named.
Price checked	Checked by a person July 14, 2026 · an automated check re-read it September 14, 2026	Checked by a person September 3, 2026 · an automated check re-read it September 14, 2026

When to choose TMates

You want a compounded program with clinical check-ins built in
You'd rather pay one bundled monthly fee than line items
You want responsive messaging with prescribers
You're comfortable with a longer onboarding intake in exchange for support

Check current TMates pricing →

When to choose Yucca Health

You want a low advertised entry price on compounded semaglutide or tirzepatide
You value an upfront 'not FDA-approved' compounding disclosure in the FAQ
You want provider coverage in all 50 states with free 2-day shipping
You're comfortable confirming your exact ongoing rate at intake (pricing beyond the entry offer is shared after eligibility)

Check current Yucca Health pricing →

Full reviews

Frequently asked questions

Is TMates cheaper than Yucca Health?

Yucca Health starts lower on semaglutide (Compounded. Verbatim from tryyucca.com 2026-09-03: 'Semaglutide plans start at $125 per month with the 6-month plan ($750 total); the month-to-month plan is $146 per month.' The 6-month rate dropped $146 -> $125; $146 is now the published month-to-month rate. Page still notes 'Pricing is shared after intake once eligibility is confirmed.'). TMates starts lower on tirzepatide (From $167/mo (compounded tirzepatide, 12-month plan; $297/mo month-to-month)). Higher doses can shift the picture, so confirm pricing at the dose you're likely to use long-term.

Which is better for semaglutide or tirzepatide, TMates or Yucca Health?

Yucca Health tends to win on semaglutide entry pricing; TMates tends to win on tirzepatide entry pricing. Pick by which medication you'll be on long-term, not by the cheapest entry tier.

Are TMates and Yucca Health compounded or brand-name?

TMates offers compounded glp-1 with bundled clinical support. Yucca Health offers compounded semaglutide and tirzepatide, once-weekly injection ('semaglutide+' / 'tirzepatide+'); also sells nad+ and sermorelin (out of registry scope). If you specifically want brand-name Wegovy or Zepbound, lean toward whichever explicitly supports brand access; if compounded is fine, both can typically meet that need.

Can I switch from TMates to Yucca Health?

Yes, switching between TMates and Yucca Health is straightforward in most states. You typically finish your current month, complete a new intake with the other provider, and they handle the prescription. Watch for overlap on auto-renewal billing and confirm any dose-tier or formulation differences with the new clinician before your next shipment.

Compare TMates and Yucca Health to other programs

Alert me when this gets cheaper

These prices move. Get one email when we publish a verified price drop, the programs on this list included. No spam. Unsubscribe any time.

Related guides

About compounded GLP-1 medicationsCompounded semaglutide and tirzepatide are not FDA-approved finished products. They are prepared by state-licensed 503A pharmacies or 503B outsourcing facilities and are not individually reviewed by the FDA for safety, effectiveness, or quality. Compounders describe these preparations as using the same active ingredient as the approved medicines; the FDA has warned that some compounded products use salt forms, semaglutide sodium or semaglutide acetate, that it considers different active ingredients from the approved drug, and has issued warning letters over marketing that presents a compounded preparation as interchangeable with an approved one. The FDA declared the semaglutide shortage resolved on February 21, 2025 and the tirzepatide shortage resolved in December 2024, so the shortage-era pathway for broad compounding of these drugs has ended. Compounding now proceeds under the ordinary rules: a 503A pharmacy compounding for an individual patient on a prescription, or a 503B outsourcing facility, which compounds in bulk under CGMP and FDA registration rather than per patient. Those rules generally do not cover a product that is “essentially a copy” of an approved drug unless a prescriber documents a change that makes a significant difference for an individual patient. Talk to a clinician about contraindications including personal or family history of medullary thyroid carcinoma or MEN 2. RangeYourself does not provide medical advice, does not guarantee a prescription, and does not guarantee weight-loss results.

RangeYourself is reader-supported. We may earn a commission when you click on certain links, at no extra cost to you. Editorial recommendations are made independently. Pricing reflects publicly listed entry tiers, verified on the dates shown in the table above, and may change. Numbers like $158/mo (compounded semaglutide, 12-month plan; $249/mo month-to-month); medication and visits included and Compounded. Verbatim from tryyucca.com 2026-09-03: 'Semaglutide plans start at $125 per month with the 6-month plan ($750 total); the month-to-month plan is $146 per month.' The 6-month rate dropped $146 -> $125; $146 is now the published month-to-month rate. Page still notes 'Pricing is shared after intake once eligibility is confirmed.' are starting tiers, not your guaranteed long-term cost.